Drug Trial Radar · NCT05940428
A Study of ASKG712 in Patients With Diabetic Macular Edema
Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Oct 23, 2023
Primary completion
Oct 21, 2024
Study completion Oct 21, 2024
Sponsor
- Lead sponsor
- Visara, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Suzhou Aosaikang Biopharmaceutical Co., Ltd.; AskGene Pharma, Inc.
- First posted
- Jul 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, non-randomized, open-label, multiple-dose-escalation and dose-expansion study will investigate the safety, tolerability, pharmacokinetics and efficacy of ASKG712 following intravitreal administration in patients with diabetic macular edema (DME).
Conditions
- Diabetic Macular Edema
Interventions
ASKG712Biological
ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of ocular adverse events (AEs) of the study eyesTime frame: 24 weeks
- Incidence of non-ocular AEsTime frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.